REG - ABCAM Plc - Year-end Trading Update
For best results when printing this announcement, please click on the link below:
http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20100715:nRSO3782Pa
RNS Number : 3782P
ABCAM Plc
15 July 2010
For immediate release 15 July 2010
ABCAM PLC
("Abcam" or "the Company")
Year-end Trading Update
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company which markets antibodies via its own online
catalogue, is pleased to announce a pre-close trading update ahead of its results for the year ended 30 June 2010.
The Board has been pleased with the level of trading in the second half of the year, which has been strong despite the
uncertainties in the global economic environment. Overall, sterling has been weaker than in the first half of the year and
this has boosted sales more than was expected.
During the period we continued our policy of tight cost control both for cost of goods and other operating expenses.
Together with the positive effect of exchange rates, this has contributed to higher gross margins, and allowed us to
benefit from the operational gearing of the business. Overall this means that we anticipate that the profit before tax for
the year will be around 9% ahead of current market consensus.
Our online catalogue has continued to grow, comprising 63,000 products at the year end, of which the majority are
antibodies. The protein detection and regulation markets are exciting ones to be in and we believe that we are well placed
within them to build on our strong market position and expertise. It is encouraging that they continue to demonstrate the
defensive qualities shown through the recent economic turbulence. However Governments and companies around the world are
still affected by the legacy of the recession and it is unclear whether this may have any impact on our business.
The preliminary results for the 2010 financial year will be announced in the week commencing 6 September 2010.
For further information please contact:
Abcam + 44 (0) 1223 696000
Jonathan Milner, Chief Executive Officer
Jeff Iliffe, Chief Financial Officer
www.abcam.com
Numis Securities + 44 (0) 20 7260 1000
Michael Meade / Nick Westlake - Nominated Adviser
James Black - Corporate Broking
Buchanan Communications + 44 (0) 20 7466 5000
Mark Court / Stasa Filiplic
Notes for editors
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with
subsidiaries in Cambridge, Massachusetts, Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under
the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies and related
products to academic and commercial users throughout the world. Product ordering is available through the Company's website
www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the
antibodies are sold under the Abcam brand name. Abcam's mission is to develop the largest catalogue of the best antibodies
in the world, with the vision of becoming a global leader in the wider protein detection and regulation markets. Abcam now
has a rapidly growing online catalogue and as at 30 June 2010 it contained 63,000 products, most of which are antibodies,
from over 250 suppliers. Abcam employs 270 staff in its four operating companies.
About antibodies
Antibodies are proteins produced by white blood cells in response to the introduction of a foreign body known as an
antigen. Antibodies, which have a wide variety of uses in research, diagnostics and therapeutics, are used by bioscientists
in research into disease and into the human genome, where they are used to mark and identify specific cells and other
living matter. The number of human antibodies of use in research is potentially greater than one million.
This information is provided by RNS
The company news service from the London Stock Exchange
back to RNS news